S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:IKNA

Ikena Oncology - IKNA Stock Forecast, Price & News

$4.20
-0.06 (-1.41%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.20
$4.45
50-Day Range
$2.22
$4.48
52-Week Range
$1.94
$11.79
Volume
1.51 million shs
Average Volume
26,963 shs
Market Capitalization
$152.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Ikena Oncology MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
352.4% Upside
$19.00 Price Target
Short Interest
Bearish
8.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.02) to ($2.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

841st out of 1,053 stocks

Biological Products, Except Diagnostic Industry

138th out of 170 stocks


IKNA stock logo

About Ikena Oncology (NASDAQ:IKNA) Stock

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

IKNA Stock News Headlines

Ikena Oncology (NASDAQ:IKNA) Trading 9.3% Higher
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Ikena Oncology: Q3 Earnings Insights
Ikena Oncology Inc IKNA Sustainability
Ikena Oncology, Inc. Misses Q2 EPS by 8c
Ikena Oncology: Q2 Earnings Insights
See More Headlines
Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

IKNA Company Calendar

Last Earnings
11/07/2022
Today
2/02/2023
Next Earnings (Estimated)
3/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IKNA
Fax
N/A
Employees
67
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+352.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-34,120,000.00
Pretax Margin
-172.89%

Debt

Sales & Book Value

Annual Sales
$30.99 million
Book Value
$5.78 per share

Miscellaneous

Free Float
34,513,000
Market Cap
$152.29 million
Optionable
Not Optionable
Beta
0.80

Key Executives

  • Dr. Mark Manfredi Ph.D. (Age 51)
    Pres. CEO & Director
    Comp: $795k
  • Dr. Sergio L. Santillana M.B.A. (Age 59)
    M.D., M.Sc., MSc, Chief Medical Officer
    Comp: $616k
  • Dr. Jotin Marango M.D. (Age 43)
    Ph.D., CFO & Head of Corp. Devel.
  • Dr. Michelle Zhang Ph.D.
    Chief Scientific Officer
  • Ms. Samantha Vuksanic
    Head of HR
  • Mr. Jeffrey Ecsedy Ph.D. (Age 52)
    Chief Devel. Officer
  • Mr. Alfredo Castro Ph.D.
    Exec. VP of Discovery
  • Mr. Alexander Constan Ph.D.
    Sr. VP of Non Clinical Safety & DMPK
  • Ms. Jennifer Schroeder
    Sr. VP of Clinical Devel. Operations
  • Mr. Evan A. Hecker Ph.D.
    Sr. VP & Head of CMC













IKNA Stock - Frequently Asked Questions

Should I buy or sell Ikena Oncology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IKNA shares.
View IKNA analyst ratings
or view top-rated stocks.

What is Ikena Oncology's stock price forecast for 2023?

2 brokerages have issued 1 year price objectives for Ikena Oncology's stock. Their IKNA share price forecasts range from $16.00 to $22.00. On average, they expect the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 352.4% from the stock's current price.
View analysts price targets for IKNA
or view top-rated stocks among Wall Street analysts.

How have IKNA shares performed in 2023?

Ikena Oncology's stock was trading at $2.66 on January 1st, 2023. Since then, IKNA stock has increased by 57.9% and is now trading at $4.20.
View the best growth stocks for 2023 here
.

When is Ikena Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023.
View our IKNA earnings forecast
.

How were Ikena Oncology's earnings last quarter?

Ikena Oncology, Inc. (NASDAQ:IKNA) released its earnings results on Monday, November, 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.02. The firm earned $6.40 million during the quarter, compared to analyst estimates of $3.83 million.

When did Ikena Oncology IPO?

(IKNA) raised $125 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO.

What is Ikena Oncology's stock symbol?

Ikena Oncology trades on the NASDAQ under the ticker symbol "IKNA."

How do I buy shares of Ikena Oncology?

Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ikena Oncology's stock price today?

One share of IKNA stock can currently be purchased for approximately $4.20.

How much money does Ikena Oncology make?

Ikena Oncology (NASDAQ:IKNA) has a market capitalization of $152.29 million and generates $30.99 million in revenue each year. The company earns $-34,120,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

How can I contact Ikena Oncology?

Ikena Oncology's mailing address is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. The official website for the company is ikenaoncology.com. The company can be reached via phone at 857-273-8343 or via email at info@ikenaoncology.com.

This page (NASDAQ:IKNA) was last updated on 2/2/2023 by MarketBeat.com Staff